Description: Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
Home Page: www.viracta.com
VIRX Technical Analysis
2533 South Coast Highway 101
Cardiff-by-the-Sea,
CA
92007
United States
Phone:
858 400 8470
Officers
| Name | Title |
|---|---|
| Mr. Daniel R. Chevallard | CFO, COO & Sec. |
| Dr. Lisa Rojkjaer | Chief Medical Officer |
| Mr. Mark Andrew Rothera | CEO, Pres & Director |
| Dr. Susan Perrine M.D. | Scientific Founder and Consultant |
| Dr. Ronald J. Berenson M.D. | Co-Founder and Consultant |
| Mr. George Hillman | Co-Founder |
| Dr. Thalia Papayannopoulou M.D. | Co-Founder |
| Dr. Robert M. Williams Ph.D. | Co-Founder |
| Dr. Douglas V. Faller M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Dr. Ayman El-Guindy | Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.2081 |
| Price-to-Book MRQ: | 1.1822 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2005-09-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |